NCT04690036

PD-1 Antibody for Reactive EBV After BMT

Reactivation of EBV for Patients With CAEBV and EBV Associated HLH After Transplantation

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Beijing Friendship Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

PD-1 antibody for reactivation of EBV after transplantation in patients with CAEBV/EBV-HLH

Detailed description

Transplantaion is recongnized as a cure for CAEBV and EBV associated HLH，however, many patients undergo the reactivation of EBV after transpaltion, patiens may at high risk for recurrence of the disease. PD-1 is a promising therapy to solve this problem. The present study was a one-arm clinical study, the main subject is to evaluate the effect of PD-1 antibody on the clearance of EBV

Conditions

• PD-1
• EBV Infection
• Transplant

Interventions

Type	Name	Description
DRUG	toripalimab injection	when EBV-DNA is positive after allo-HCT, and EBV infected T/NK cell, one dose of toripalimab 3mg/kg would be used, the same dose would be repeated 4 weeks later.

Timeline

• Start date: 2021-07-01
• Primary completion: 2023-01-01
• Completion: 2023-01-01
• First posted: 2020-12-30
• Last updated: 2021-06-29

Locations

1 site across 1 country: China